Nan Bi

机构：Binghamton University, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center · ORCID：0000-0001-7201-2930

发表论文 419 篇 · 总被引 5533 次 · h-index 38

代表论文

• Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial (2025 · The Lancet Oncology · 被引 15)
• Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients (2025 · Signal Transduction and Targeted Therapy · 被引 11)
• PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (2025 · Journal of Hematology & Oncology · 被引 10)
• Gut microbiota predictive of the efficacy of consolidation immunotherapy and chemoradiotherapy toxicity in lung cancer (2025 · Med · 被引 9)
• Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study (2025 · Lung Cancer · 被引 7)
• The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy (2025 · Journal of Translational Medicine · 被引 4)